Late-breaker presentation selected as “Best of ILC”The 24-week Phase 2 study met its primary endpoint, achieving a statistically significant reduction […]
Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPASignificant coronary plaque regression of low attenuation […]